Scientists More Effectively Control Pain by Targeting Nerve Cell’s Interior

New research indicates that the location of receptors that transmit pain signals IS important in how big or small a pain signal will be and how effectively drugs can block those signals.

In real estate, location is key. It now seems the same concept holds true when it comes to stopping pain.

New research at Washington University School of Medicine in St. Louis and McGill University in Montreal indicates that the location of receptors that transmit pain signals IS important in how big or small a pain signal will be and how effectively drugs can block those signals.

Blocking pain receptors in the nucleus of spinal nerve cells could control pain more effectively than interfering with the same type of receptors located on cell surfaces, the research shows. The scientists also found that when those same nerve cells encounter a painful stimulus, some of the receptors migrate from the cell surface into the nucleus.

“Chronic pain affects almost 30 percent of Americans, and we’ve found, in rats, that by blocking specific receptors inside the cell, we can block pain,” said co-senior author Karen O’Malley, PhD, a professor of neuroscience at Washington University. “If we can find ways to specifically block pain receptors inside of cells rather than on the cell surface, we may make a big dent in chronic pain with fewer drug-induced side effects.”

The study is published online Feb. 3 in the journal Nature Communications.

The researchers focused on a specific type of glutamate receptor that is part of the family of receptors called G-protein-coupled receptors, which are important in signaling between neurons.

In a rat model that mimics a type of chronic, neuropathic pain, animals treated with investigational drugs to block the activity of the receptors in the nucleus responded in ways suggesting they had gotten relief from their pain.

“Drugs that penetrate the spinal nerve cells to block receptors at the nucleus were effective at relieving neuropathic pain, but those that didn’t penetrate the cells were not,” said McGill’s Terence J. Coderre, PhD, who developed the rat model.

Coderre also explained that rats with nerve injuries displayed less spontaneous pain and less hypersensitivity to a painful stimulus when those nuclear receptors were blocked. But normal rats without nerve injuries had no changes in pain sensitivity when those receptors were blocked and the animals were exposed to a painful stimulus.

“This is the first time we’ve been able to demonstrate that receptors inside the cell, on the nucleus, affect behavior in living animals,” O’Malley said.

Coderre quipped: “By engineering drugs to target glutamate receptors at the nucleus, I guess you could say that pain treatment has gone nuclear.”

Scientists have been studying glutamate receptors in the pain pathway for decades. What’s new, O’Malley explained, is that these most recent experiments — in cell cultures and rats — demonstrate that the location of the receptor in the cell has a major effect on the cell’s ability to transmit pain signals.

For example, the researchers found that when these particular glutamate receptors on the nucleus of a nerve cell were activated, the response — measured by the amount of calcium released— was nine times larger than when the same type of receptor was activated on the cell’s surface. Changes in calcium levels play a key role in signaling in neurons. Increased calcium can release important neurotransmitters, regulate specific genes and contribute to synaptic changes that are critical to pain signals.

“The nuclear calcium response goes up and stays up for a significant period of time — about four minutes,” O’Malley said. “The increased levels of nuclear calcium activate pathways that carry pain signals from the nerves to the brain.”

They also found that the glutamate receptors on the nucleus responded to painful stimuli more robustly than the same types of receptors located on the cell’s surface, and that when the cells encountered such a stimulus, some receptors migrated from the surface to the nucleus. The researchers also discovered that receptors located in the nucleus stopped activating pain signals when targeted with drugs.

The researchers focused mainly on nerve cells in the spinal cord, an important area for transmitting pain signals coming from all parts of the body. Future research will be aimed at determining what events cause the glutamate receptors to migrate to the nucleus and how to make drugs that more specifically block only glutamate receptors in the nucleus of the nerve cells.



More in Clinical

Clinical  May 04

The Pill, Prescriptions, Pharmacists & Physicians

‘The Pill’ made headlines and stirred up controversy in the late 1950s and early 1960s as the nation debated whether or not women…

Clinical  Apr 21

The Bidens at AACR

On April 20, Vice President Joe Biden and Jill Biden, EdD, addressed over 4,000 attendees during the American Association for Cancer…

Clinical  Apr 12

Zika Legislation Headed to President's Desk

On April 12, Chairman Lamar Alexander (R-Tenn.) made the following statement as Senate health committee-passed legislation to spur…

Business  Apr 07

Planning for Long-Term Care

“A man who procrastinates in his choosing will inevitably have his choice made for him by circumstance.” – Hunter S. Thompson

Clinical  Apr 07

Plan to Address Mental Health Crisis

A bipartisan U.S. Senate group looks to ease the burden on Americans suffering from mental health and substance abuse disorders…

Clinical  Apr 06

Artificial Intelligence, Real Results

Developers have created a new tool that combines predictive analytics with artificial intelligence to improve outcomes and decrease…

Clinical  Apr 06

Surgeons Test Technology with Potential to Expand Lung Transplant Donor Pool

Organ transplant patient Michele Coleman receives a follow-up exam a few months after surgeons at Washington University School of Medicine in St. Louis gave her a new set of lungs.

Clinical  Mar 29

AMA on Ending Opioid Epidemic

Opioid and heroin abuse have skyrocketed in America prompting new guidelines and regulations from the CDC and FDA. The AMA weighed in…

Clinical  Mar 28

Cells Have Strategies to Get Back on Track After Replication Stress

In a recent review paper published in Nature Structural & Molecular Biology, Saint Louis University scientist Alessandro Vindigni, Ph.D., describes the strategies cells use when their DNA faces replication stress, challenges that may derail a…

Clinical  Mar 03

Findings may guide design of new drugs

Genetic errors identified in a new study led by Washington University School of Medicine in St. Louis may reduce risk of heart attacks…

Business  Feb 29

‘Trigger Tool’ Available for Hospitals and SNFs

How can ‘trigger tools’ identify adverse events?

Clinical  Feb 29

Cancer Stats & Facts

Each year the American Cancer Society releases the latest data as a litmus test of where the nation stands in the fight against cancer.

Clinical  Feb 24

Technology may improve treatment for deadly brain cancer

Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain’s protective…

Clinical  Feb 23

Ending the Opioid Epidemic

Read the Feb. 22 joint statement by National Governors Association Health & Human Services Committee Chair Massachusetts Gov. Charlie Baker; Vice Chair New Hampshire Gov. Maggie Hassan; American Medical Association Chair-Elect Patrice A. Harris, MD, MA

Business  Feb 08

Challenging Population Health Management Issues

The nation’s leading forum on innovations in population health is slated for March 7-9 in Philadelphia.

Clinical  Feb 08

Prevent, Protect, Improve

Healthways and Dr. Dean Ornish have teamed up on a secondary intervention proven to not only treat heart disease but also to reverse…

Clinical  Feb 08

The 7th Character

How important is the 7th character for Medicare/Medicaid claims?

Business  Jan 26

Taken for Granted: A New Era in Care – the New SSM Health Saint Louis University Hospital

Patient-centered design will enhance the new state-of-the-art academic facilities.

Clinical  Jan 26

New Outpatient Care Center Under Construction in South St. Louis County

Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital (BJH) are building a new outpatient facility in south…

Clinical  Jan 26

Bhayani Named Holekamp Family Chair in Urology

Sam Bhayani, MD, who recently was appointed chief medical officer of the Faculty Practice Plan at Washington University School of Medicine in St. Louis, has been named the Holekamp Family Chair in Urology at Barnes-Jewish Hospital (BJH) and the School

Clinical  Jan 18

Team Develops Wireless, Dissolvable Sensors to Monitor Brain

A team of neurosurgeons and engineers has developed wireless brain sensors that monitor intracranial pressure and temperature and then…

  Load more content